期刊文献+

Expression of Ki-67,p53,and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma 被引量:4

Expression of Ki-67,p53,and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma
下载PDF
导出
摘要 AIM: To examine surgical specimens of pancreas with either chronic pancreatitis or pancreatic cancer in order to study whether ductal hyperplasia and dysplasia in pancreas represent precursor lesions for pancreatic cancer. METHODS: We examined expression of Ki-67, CEA, p53, and K-ras, in the surgical specimens of pancreas with adenocarcinomas (n = 11) and chronic pancreatitis (n = 12). Cellular proliferation was assessed by Ki-67 proliferation index using the proliferation marker Ki-67. In specimens with pancreas cancer, we divided pancreas epithelium into normal (n = 7), ductal hyperplasia (n = 3), dysplasia (n = 4), and cancerous lesion (n = 11) after hematoxylin and eosin staining, Ki-67, and CEA immunohistochemical staining. In cases with chronic pancreatitis, the specimen was pathologically examined as in cases with pancreas cancer, and they were also determined as normal (n = 10), ductal hyperplasia (n = 4), or dysplasia (n = 5). p53 and K-ras expression were also studied by immunohistochemical staining. RESULTS: In pancreatic cancer, the Ki-67 index was 3.73±3.58 in normal site, 6.62±4.39 in ductal hyperplasia, 13.47:1:4.02 in dysplasia and 37.03±10.05 in cancer tissue, respectively. Overall, p53 was positive in normal ducts, ductal hyperplasia, dysplasia, and carcinoma cells in 0 of 14 (0%), 0 of 7 (0%), 7 of 9 (78%), and 10 of 11 (91%), respectively, and K-ras was positive in 0 of 8 (0%), 1 of 3 (33%), 4 of 6 (67%), 4 of 5 (80%), respectively. CONCLUSION: Our results favorably support the hypothesis that ductal hyperplasia and dysplasia of the pancreas might be precursor lesions for pancreas cancer. Further evaluation of oncogenes by the molecular study is needed. AIM: To examine surgical specimens of pancreas with either chronic pancreatitis or pancreatic cancer in order to study whether ductal hyperplasia and dysplasia in pancreas represent precursor lesions for pancreatic cancer.METHODS: We examined expression of Ki-67, CEA,p53, and K-ras, in the surgical specimens of pancreas with adenocarcinomas (n = 11) and chronic pancreatitis (n = 12). Cellular proliferation was assessed by Ki-67proliferation index using the proliferation marker Ki-67.In specimens with pancreas cancer, we divided pancreas epithelium into normal (n=7), ductal hyperplasia (n=3), dysplasia (n=4), and cancerous lesion (n=11) after hematoxylin and eosin staining, Ki-67, and CEA immunohistochemical staining. In cases with chronic pancreatitis, the specimen was pathologically examined as in cases with pancreas cancer, and they were also determined as normal (n=10), ductal hyperplasia (n=4), or dysplasia (n= 5). p53 and K-ras expression were also studied by immunohistochemical staining.RESULTS: In pancreatic cancer, the Ki-67 index was 3.73±3.58 in normal site, 6.62±4.39 in ductalhyperplasia, 13.47±4.02 in dysplasia and 37.03±10.05in cancer tissue, respectively. Overall, p53 was positive in normal ducts, ductal hyperplasia, dysplasia, and carcinoma cells in 0 of 14 (0%), 0 of 7 (0%), 7 of 9 (78%),and 10 of 11 (91%), respectively, and K-ras was positive in 0 of 8 (0%), 1 of 3 (33%), 4 of 6 (67%), 4 of 5 (80%),respectively.CONCLUSION: Our results favorably support the hypothesis that ductal hyperplasia and dysplasia of the pancreas might be precursor lesions for pancreas cancer.Further evaluation of oncogenes by the molecular study is needed.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第43期6765-6769,共5页 世界胃肠病学杂志(英文版)
基金 Supported by the Inha University Research Grant 2005
关键词 KI-67 P53 K-RAS Chronic pancreatitis Pancreatic ductal adenocarcinoma Ki-67 p53 K-ras 基因表达 慢性胰腺炎 胰腺导管癌
  • 相关文献

参考文献24

  • 1[1]Warshaw AL,Fernandez-del Castillo C.Pancreatic carcinoma.N Engl JMed 1992; 326:455-465
  • 2[2]Boyle P,Hsieh CC,Maisonneuve P,La Vecchia C,Macfarlane GJ,Walker AM,Trichopoulos D.Epidemiology of pancreas cancer (1988).Int J Pancreatol 1989; 5:327-346
  • 3[3]Wingo PA,Tong T,Bolden S.Cancer statistics,1995.CA Cancer J Clin 1995; 45:8-30
  • 4[4]Crist DW,Cameron JL.The current status of the Whipple operation for periampullary carcinoma.Adv Surg 1992; 25:21-49
  • 5[5]Lowenfels AB,Maisonneuve P,Cavallini G,Ammann RW,Lankisch PG,Andersen JR,Dimagno EP,Andren-Sandberg A,Domellof L.Pancreatitis and the risk of pancreatic cancer.International Pancreatitis Study Group.N Engl J Med 1993; 328:1433-1437
  • 6[6]Cubilla AL,Fitzgerald PJ.Morphological lesions associated with human primary invasive nonendocrine pancreas cancer.Cancer Res 1976; 36:2690-2698
  • 7[7]Kozuka S,Sassa R,Taki T,Masamoto K,Nagasawa S,Saga S,Hasegawa K,Takeuchi M.Relation of pancreatic duct hyperplasia to carcinoma.Cancer 1979; 43:1418-1428
  • 8[8]SOMMERS SC,MURPHY SA,WARREN S.Pancreatic duct hyperplasia and cancer.Gastroenterology 1954; 27:629-640
  • 9[9]Apple SK,Hecht JR,Lewin DN,Jahromi SA,Grody WW,Nieberg RK.Immunohistochemical evaluation of K-ras,p53,and HER-2/neu expression in hyperplastic,dysplastic,and carcinomatous lesions of the pancreas:evidence for multistep carcinogenesis.Hum Pathol 1999; 30:123-129
  • 10[10]Kloppel G.Pancreatic Pathology.Edinburg,Scotland:Churchill Livingstone,1984:79-113

同被引文献40

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部